Colon cancer , a major contributor to cancer-related mortality, has been linked to improved outcomes with aspirin and selective cyclooxygenase inhibitor use, though benefits are not uniform across all patients. To clarify the role of postoperative circulating tumor DNA in guiding adjuvant therapy, a study evaluated survival outcomes with the addition of celecoxib to standard chemotherapy in patients with stage III colon cancer, involving 940 patients with a mean age of 60.9 years. The study showed that patients with positive postoperative ctDNA had markedly worse disease-free and overall survival than those who were ctDNA negative.
In this high-risk group, treatment with celecoxib was associated with significant improvements in both disease-free survival (adjusted HR = 0.61) and overall survival (adjusted HR = 0.62) compared with placebo. Conversely, celecoxib did not confer a…
